Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBT (2020 - 2025)

Historic EBT for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Mirum Pharmaceuticals' EBT rose 11903.08% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.8 million, marking a year-over-year increase of 5832.82%. This contributed to the annual value of -$86.9 million for FY2024, which is 4649.07% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its EBT stood at $2.6 million for Q3 2025, which was up 11903.08% from -$5.5 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' EBT ranged from a high of $57.3 million in Q4 2021 and a low of -$73.7 million during Q2 2023
  • Its 5-year average for EBT is -$25.9 million, with a median of -$29.9 million in 2023.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EBT surged by 25356.49% in 2021, and later plummeted by 16334.39% in 2022.
  • Mirum Pharmaceuticals' EBT (Quarter) stood at $57.3 million in 2021, then plummeted by 163.34% to -$36.3 million in 2022, then increased by 2.36% to -$35.4 million in 2023, then soared by 31.24% to -$24.4 million in 2024, then skyrocketed by 110.85% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, -$5.5 million for Q2 2025, and -$13.6 million during Q1 2025.